CMS approves TearLab’s reconsideration request

The Centers for Medicare and Medicaid Services (CMS) has published instructions for updates to the clinical laboratory fee schedule for 2012, including a revised reimbursement rate for the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity Test, effective Jan. 1. The payment code of 83861 that currently applies to the TearLab test for diagnosing Dry Eye Disease will be [...]

TearLab taps social media for dry eye awareness

During the past six months, TearLab (NASDAQ:TEAR;TSX:TLB) has initiated a series of social media campaigns as part of an innovative strategy to increase the awareness of dry eye disease (DED) with both patients and doctors. The program is also designed to demonstrate how its diagnostic test for dry eye can change the paradigm of dry [...]

World-renowned ophthalmologist, Dr. Marguerite McDonald, on managing dry eye patients with TearLab

In an interview with Ophthalmology Web, Dr. Marguerite McDonald discusses the benefits of incorporating the TearLab (NASDAQ:TEAR; TSX:TLB) Osmolarity System to manage dry eye patients more effectively. Dr. McDonald said that having an objective measurement provided by the TearLab device creates efficiencies in dry eye patient management, as well as providing practice differentiation. Dry eye [...]

TearLab set to join Russell Microcap Index

TearLab (NASDAQ:TEAR; TSX:TLB) is set to join the Russell Microcap Index when Russell Investments updates its comprehensive set of U.S. and global equity indexes after the close of trading this Friday, according to a preliminary list of additions posted recently on the Russell website. Membership in the Russell Microcap Index, which remains in place for [...]

TearLab readies overhaul of dry eye market

In the 1990s, Elias Vamvakas turned TLC Laser Vision into a medical success story, freeing hundreds of thousands of people from wearing glasses and contact lenses.  Now, he’s back at the helm of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB)) with a groundbreaking diagnostic test for dry eye disease or DED. “While laser vision correction surgery was [...]

TearLab technology validated in peer-review journal

TearLab’s (NASDAQ:TEAR;TSX:TLB) point-of-care osmolarity test is the technology of choice to aid in the diagnosis of Dry Eye Disease (“DED”) according to a peer-reviewed article published in the current issue of Contact Lens & Anterior Eye, the official journal of the British Contact Lens Association. The article states that while tear osmolarity has proven to [...]

Ottawa gives green light to TearLab osmolarity test for Dry Eye Disease

Health Canada has issued a medical device license for the TearLab Osmolarity System, which measures the osmolarity of human tears to aid in the diagnosis of Dry Eye Disease.  This clears TearLab Corp. (NASDAQ:TEAR; TSX:TLB) to immediately begin marketing the test to Canadian optometrists and ophthalmologists. The system “offers a rapid and very easy to [...]